Kura Oncology Reports Positive Data for KOMZIFTI Triplet Combo in AML Trial
I'm PortAI, I can summarize articles.
Kura Oncology and Kyowa Kirin announced positive data from the KOMET-007 trial for KOMZIFTI in AML treatment. The trial showed an 86% composite complete remission rate and a 73% complete remission rate in newly diagnosed NPM1-mutant AML patients. The triplet combo was well tolerated with no increased toxicity. Results were presented at the ASH 2025 meeting, and slides are available on Kura Oncology's website.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments